Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Smith

Showing results (491-500 of 530) with videos related to

Pageof 53
Sort By:
European Journal of Pharmacology|August 31, 2020
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseasesMaryanne Covington, Xin He, Monika Scuron, et al.
Regulatory Toxicology and Pharmacology : RTP|October 28, 2015
A global initiative to refine acute inhalation studies through the use of 'evident toxicity' as an endpoint: Towards adoption of the fixed concentration procedureFiona Sewell, Ian Ragan, Tim Marczylo, et al.
Frontiers in Immunology|July 9, 2019
Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus MonkeysDiethilde Theil, Paul Smith, Catherine Huck, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study IIMarco Vincenzo Lenti, Vivien Dolby, Tanya Clark, et al.
Pediatrics|September 18, 2020
IDeA States Pediatric Clinical Trials Network for Underserved and Rural CommunitiesRobert D Annett, Sheva Chervinskiy, Thomas H Chun, et al.
Cancers|June 1, 2019
PARP Inhibition Increases the Response to Chemotherapy in Uveal MelanomaLeanne de Koning, Didier Decaudin, Rania El Botty, et al.
Physiological Genomics|December 24, 2009
EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severityRebecca Darrah, Edward McKone, Clare O'Connor, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
British Journal of Haematology|November 28, 2008
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trialBarry W Hancock, Wendi Qian, David Linch, et al.
Nature Communications|December 12, 2022
Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancerSally J Adua, Anna Arnal-Estapé, Minghui Zhao, et al.
Pageof 53

Showing results (491-500 of 530) with videos related to

Sort By:
Pageof 53
European Journal of Pharmacology|August 31, 2020
Preclinical characterization of itacitinib (INCB039110), a novel selective inhibitor of JAK1, for the treatment of inflammatory diseasesMaryanne Covington, Xin He, Monika Scuron, et al.
Regulatory Toxicology and Pharmacology : RTP|October 28, 2015
A global initiative to refine acute inhalation studies through the use of 'evident toxicity' as an endpoint: Towards adoption of the fixed concentration procedureFiona Sewell, Ian Ragan, Tim Marczylo, et al.
Frontiers in Immunology|July 9, 2019
Imaging Mass Cytometry and Single-Cell Genomics Reveal Differential Depletion and Repletion of B-Cell Populations Following Ofatumumab Treatment in Cynomolgus MonkeysDiethilde Theil, Paul Smith, Catherine Huck, et al.
Alimentary Pharmacology & Therapeutics|December 22, 2021
A propensity score-matched, real-world comparison of ustekinumab vs vedolizumab as a second-line treatment for Crohn's disease. The Cross Pennine study IIMarco Vincenzo Lenti, Vivien Dolby, Tanya Clark, et al.
Pediatrics|September 18, 2020
IDeA States Pediatric Clinical Trials Network for Underserved and Rural CommunitiesRobert D Annett, Sheva Chervinskiy, Thomas H Chun, et al.
Cancers|June 1, 2019
PARP Inhibition Increases the Response to Chemotherapy in Uveal MelanomaLeanne de Koning, Didier Decaudin, Rania El Botty, et al.
Physiological Genomics|December 24, 2009
EDNRA variants associate with smooth muscle mRNA levels, cell proliferation rates, and cystic fibrosis pulmonary disease severityRebecca Darrah, Edward McKone, Clare O'Connor, et al.
British Journal of Haematology|March 14, 2021
Using depth of response to stratify patients to front line Autologous Stem Cell Transplant: results of the phase II PADIMAC Myeloma TrialRakesh Popat, Nicholas Counsell, Ruth de Tute, et al.
British Journal of Haematology|November 28, 2008
Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trialBarry W Hancock, Wendi Qian, David Linch, et al.
Nature Communications|December 12, 2022
Brain metastatic outgrowth and osimertinib resistance are potentiated by RhoA in EGFR-mutant lung cancerSally J Adua, Anna Arnal-Estapé, Minghui Zhao, et al.
Pageof 53